Emerging concepts for the treatment of hematological malignancies with therapeutic monoclonal antibodies

Current Drug Targets

Volumn 11, Issue 7, 2010, Pages 790-800

  Capietto, Aude Hélène ^a,b   Keirallah, Samarh ^a,b   Gross, Emilie ^a,b   Dauguet, Nicolas ^a,b   Laprévotte, Emilie ^a,b   Jean, Christine ^a,b   Gertner Dardenne, Julie ^c   Bezombes, Christine ^a,b   Quillet Mary, Anne ^a,b   Poupot, Mary ^a,b   Ysebaert, Loic ^a,b   Laurent, Guy ^a,b   Fournié, Jean Jacques ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c INSTITUT PAOLI CALMETTES   (France)

Author keywords

Antibodies; Cancer; Lymphoma; Phosphoantigens; Therapy

Indexed keywords

1 7 F 9; ALEMTUZUMAB; APOLIZUMAB; ARZERRA; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; DACLIZUMAB; DEATH RECEPTOR 4; DEATH RECEPTOR 5; EPRATUZUMAB; GALIXIMAB; GEMTUZUMAB OZOGAMICIN; HU M 195; I KAPPA B; IBRITUMOMAB TIUXETAN; IMMUNO 106; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; INOTUZUMAB OZOGAMICIN; IRATUMUMAB; KIROMAB; LINTUZUMAB; LUMILIXIMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MDX 060; OCRELIZUMAB; OFATUMUMAB; RHUMAB; RITUXIMAB; SIPLIZUMAB; TOSITUMOMAB; TOSITUMOMAB I 131; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELTUZUMAB; ZANOLIMUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CANCER THERAPY; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MULTIMODALITY CANCER THERAPY; MYELOABLATIVE CONDITIONING; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL T CELL LYMPHOMA; PHAGOCYTOSIS; SEZARY SYNDROME; T CELL LEUKEMIA; TREATMENT RESPONSE; TUMOR CELL;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DELIVERY SYSTEMS; HEMATOLOGIC NEOPLASMS; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; RECOMBINANT FUSION PROTEINS;

EID: 77954705145     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010791320845     Document Type: Article

References (140)

1. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15(10): 3266-74.
2. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90(6): 2188-95.
3. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16(8): 2825-33.
4. Ravandi F, O'Brien S. Alemtuzumab in CLL and other lymphoid neoplasms. Cancer Invest 2006; 24(7): 718-25.
5. Ehrlich P. On immunity with special reference to cell life. Proceedings of the Royal Society of London 1899-1900; 66: 424-48.
6. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256(5517): 495-7.
7. Schulz G, Buchler M, Muhrer KH, et al. Immunotherapy of pancreatic cancer with monoclonal antibody BW 494. Int J Cancer Suppl 1988; 2: 89-94.
8. Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG, Parren PW. Novel human antibody therapeutics: the age of the Umabs. Biotechnol J 2008; 3(9-10): 1157-71.
9. Neumann F, Zohren F, Haas R. The role of natalizumab in hematopoietic stem cell mobilization. Expert Opin Biol Ther 2009; 9(8): 1099-106.
10. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355(12): 1233-43.
11. Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J biol chem 2003; 278(5): 3466-73.
12. Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N- linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J biol chem 2002; 277(30): 26733-40.
13. Paintaud G, Lejarre F, Ternant D, Goupille P, Watier H. [Monoclonals antibodies: a recent and major therapeutic advance]. Therapie 2009; 64(1): 1-7.
14. Rossignol A, Watier H. Les anticorps monoclonaux: une ingéniérie technologique au service de l'efficacité thérapeutique. Hematol 2009; 15(special 3): 5-13.
15. Cartron G. [Immunologic effects of anti-B-lymphocyte antibodies]. La Revue de medecine interne/fondee 2005; 26 Spec No 1: 42-6.
16. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nature biotechnol 2005; 23(9): 1147-57.
17. Mahalingam D, Szegezdi E, Keane M, Jong S, Samali A. TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer treatment reviews 2009; 35(3): 280-8.
18. Henson ES, Johnston JB, Gibson SB. The role of TRAIL death receptors in the treatment of hematological malignancies. Leuk lymphoma 2008; 49(1): 27-35.
19. Nawrocki ST, Carew JS, Douglas L, Cleveland JL, Humphreys R, Houghton JA. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. Cancer Res 2000; 67(14): 6987-94.
20. Huang Y, Sheikh MS. TRAIL death receptors and cancer therapeutics. Toxicol Appl Pharmacol 2007; 224(3): 284-9.
21. Leseux L, Hamdi SM, Al Saati T, et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 2006; 108(13): 4156-62.
22. Leseux L, Laurent G, Laurent C, et al. PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma. Blood 2008; 111(1): 285-91.
23. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007; 26(25): 3629-36.
24. Kheirallah S, Caron P, Gross E et al. Rituximab inhibits B cell Receptor signaling. Blood 2010; 115(5): 985-94.
25. Carnahan J, Stein R, Qu Z, et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol immunol 2007; 44(6): 1331-41.
26. Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 2005; 23(22): 5044-51.
27. Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non- Hodgkin's lymphoma. J Clin Oncol 2003; 21(16): 3051-9.
28. Gelderman KA, Tomlinson S, Ross GD, Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 2004; 25(3): 158-64.
29. Dalle S, Dumontet C. [Rituximab: mechanism of action and resistance]. Bulletin du Cancer 2007; 94(2): 198-202.
30. Stolz C, Schuler M. Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention. Leuk lymphoma 2009; 50(6): 873-85.
31. Harjunpaa A, Wiklund T, Collan J, et al. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk lymphoma 2001; 42(4): 731-8.
32. Wang SY, Weiner G. Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opin Biol Ther 2008; 8(6): 759-68.
33. Golay J, Lazzari M, Facchinetti V, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001; 98(12): 3383-9.
34. Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 2008; 13(9): 954-66.
35. Natsume A, Niwa R, Satoh M. Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. Drug Des Devel Ther 2009; 3: 7-16.
36. Ito M, Omoto S, Kato Y, Hayashi T, Mori N, Fujii YR. In vivo tumouricidal effects of LAD-1 monoclonal antibody on murine RL- male-1 lymphoma mediated by enhanced phagocytosis. Clin Exp immunol 2005; 141(1): 54-61.
37. Akewanlop C, Watanabe M, Singh B, Walker M, Kufe DW, Hayes DF. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody. Cancer Res 2001; 61(10): 4061-5.
38. Wallace PK, Kaufman PA, Lewis LD, et al. Bispecific antibody- targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo. J Immunolo methods 2001; 248(1-2): 167-82.
39. Ely P, Wallace PK, Givan AL, Graziano RF, Guyre PM, Fanger MW. Bispecific-armed, interferon gamma-primed macrophage- mediated phagocytosis of malignant non-Hodgkin's lymphoma. Blood 1996; 87(9): 3813-21.
40. Shibata-Koyama M, Iida S, Misaka H, et al. Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils. Exp Hematol 2009; 37(3): 309-21.
41. Harbers SO, Crocker A, Catalano G, et al. Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. J Clin Invest 2007; 117(5): 1361-9.
42. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 2002; 110(1): 71-9.
43. Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet 2009; 373(9668): 1033-40.
44. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Med 2000; 6(4): 443-6.
45. Williams ME, Densmore JJ, Pawluczkowycz AW, et al. Thrice- weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 2006; 177(10): 7435-43.
46. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006; 176(4): 2600-9.
47. Beum PV, Mack DA, Pawluczkowycz AW, Lindorfer MA, Taylor RP. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J Immunol 2008; 181(11): 8120-32.
48. Li Y, Williams ME, Cousar JB, Pawluczkowycz AW, Lindorfer MA, Taylor RP. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. J Immunol 2007; 179(6): 4263-71.
49. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99(3): 754-8.
50. Congy-Jolivet N, Bolzec A, Ternant D, Ohresser M, Watier H, Thibault G. Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa-158V allotype. Cancer Res 2008; 68(4): 976-80.
51. Cartron G. FCGR3A polymorphism story: a new piece of the puzzle. Leuk Lymphoma 2009; 50(9): 1401-2.
52. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab- based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26(11): 1789-96.
53. Groh V, Li YQ, Cioca D, et al. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proceedings of the National Academy of Sciences of the United States of America 2005; 102(18): 6461-6.
54. Selenko N, Majdic O, Jager U, Sillaber C, Stockl J, Knapp W. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies? J Clin Immunol 2002; 22(3): 124-30.
55. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107(1): 265-76.
56. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97(1): 101-6.
57. Hainsworth JD, Burris HA, 3rd, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000; 95(10): 3052-6.
58. Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005; 23(6): 1103-8.
59. Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23(4): 705-11.
60. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17(1): 268-76.
61. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106(12): 3725-32.
62. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112(13): 4824-31.
63. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R- CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26(28): 4579-86.
64. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009; 27(10): 1607-14.
65. Czuczman MS, Thall A, Witzig TE, et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005; 23(19): 4390-8.
66. Leonard JP, Friedberg JW, Younes A, et al. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007; 18(7): 1216-23.
67. Witzig TE. Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Best Practice Research 2006; 19(4): 655-68.
68. Morschhauser F, Illidge T, Huglo D, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 2007; 110(1): 54-8.
69. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. New Engl J Med 2005; 352(5): 441-9.
70. Cheson B. Bexxar (Corixa/GlaxoSmithKline). Curr Opin Investig Drugs 2002; 3(1): 165-70.
71. Kaminski M. Bexxar, iodine I 131 tositumomab, effective in longterm follow-up of non-Hodgkin's lymphoma. Cancer Biol Ther 2007; 6(7): 996-7.
72. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7(5): 379-91.
73. Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 2008; 9(5): 435-44.
74. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomized controlled trial (RICOVER-60). Lancet Oncol 2008; 9(2): 105-16.
75. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (RFCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108(13): 4003-8.
76. Thomas DA, Ravandi F, Kantarjian H. Monoclonal antibody therapy for hairy cell leukemia. Hematol Oncol Clin North Am 2006; 20(5): 1125-36.
77. Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003; 102(8): 2741-5.
78. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005; 23(9): 1979-83.
79. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab doseescalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19(8): 2165-70.
80. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23(13): 2971-9.
81. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23(18): 4079-88.
82. Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27(4): 498-503.
83. Ravandi F, O'Brien S. Alemtuzumab. Expert review of anticancer therapy. 2005; 5(1): 39-51.
84. Keating M, Hallek M. Alemtuzumab, the first monoclonal antibody (MAb) directed against CD52. Medical oncology (Northwood, London, England) 2002; 19 Suppl: S1-2.
85. Ferrajoli A, O'Brien S, Keating MJ. Alemtuzumab: a novel monoclonal antibody. Exp Opin Biol Ther 2001; 1(6): 1059-65.
86. Fietz T, Thiel E. Antibody therapy in non-Hodgkin's lymphoma: the role of rituximab, 90Y-ibritumomab tiuxetan, and alemtuzumab. Recent Results Cancer Res 2007; 176: 153-63.
87. Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 2007; 26(25): 3644-53.
88. Ure UB, Ar MC, Salihoglu A, et al. Alemtuzumab in Sezary syndrome: efficient but not innocent. Eur J Dermatol 2007; 17(6): 525-9.
89. Morris JC, Waldmann TA. Antibody-based therapy of leukaemia. Expert Rev Mol Med 2009; 11:e29.
90. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008; 111(3): 1094-100.
91. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008; 111(12): 5486-95.
92. Leonard JP, Goldenberg DM. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 2007; 26(25): 3704-13.
93. Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 2007; 67(3): 333-50.
94. Reichert JM. Technology evaluation: lumiliximab, Biogen Idec. Curr Opin Mol Ther 2004; 6(6): 675-83.
95. Byrd JC, Kipps TJ, Flinn IW, et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2009 Oct 20.
96. Pathan NI, Chu P, Hariharan K, Cheney C, Molina A, Byrd J. Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. Blood 2008; 111(3): 1594-602.
97. Byrd JC, O'Brien S, Flinn IW, et al. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2007; 13(15 Pt 1): 4448-55.
98. Rech J, Repp R, Rech D, et al. A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colonystimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study. Leuk lymphoma 2006; 47(10): 2147-54.
99. Bowles JA, Weiner GJ. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods 2005; 304(1-2): 88-99.
100. Mavromatis BH, Cheson BD. Novel therapies for chronic lymphocytic leukemia. Blood Rev 2004; 18(2): 137-48.
101. Adkins D, Ratanatharathorn V, Yang H, White B. Safety profile and clinical outcomes in a phase I, placebo-controlled study of siplizumab in acute graft-versus-host disease. Transplant 2009; 88(2): 198-202.
102. O'Mahony D, Morris JC, Stetler-Stevenson M, et al. EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clin Cancer Res 2009; 15(7): 2514-22.
103. Waldmann TA. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene 2007; 26(25): 3699-703.
104. Koon HB, Severy P, Hagg DS, et al. Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. Leukemia Res 2006; 30(2): 190-203.
105. Grigg A. Daclizumab in anaplastic large cell lymphoma. Leuk Lymphoma 2006; 47(1): 175.
106. Linden O. Remission of a refractory, anaplastic large-cell lymphoma after treatment with daclizumab. New Engl J Med 2004; 351(14): 1466-7.
107. Rider DA, Havenith CE, de Ridder R, et al. A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer Res 2007; 67(20): 9945-53.
108. Villadsen LS, Skov L, Dam TN, et al. In situ depletion of CD4+ T cells in human skin by Zanolimumab. Arch Dermatol Res 2007; 298(9): 449-55.
109. Kim YH, Duvic M, Obitz E, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007; 109(11): 4655-62.
110. Mestel DS, Beyer M, Mobs M, Steinhoff M, Sterry W, Assaf C. Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sezary syndrome. Exp Opin Biol Ther 2008; 8(12): 1929-39.
111. McGavin JK, Spencer CM. Gemtuzumab ozogamicin. Drugs 2001; 61(9): 1317-22; discussion 23-4.
112. Stasi R, Evangelista ML, Buccisano F, Venditti A, Amadori S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat Rev 2008; 34(1): 49-60.
113. Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leuk 2005; 19(2): 176-82.
114. Golay J, Di Gaetano N, Amico D, et al. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. Br J Haematol 2005; 128(3): 310-7.
115. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009; 27(4): 504-10.
116. Linenberger ML, Hong T, Flowers D, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001; 98(4): 988-94.
117. Walter RB, Gooley TA, van der Velden VH, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007; 109(10): 4168-70.
118. Glatting G, Muller M, Koop B, et al. Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia. J Nucl Med 2006; 47(8): 1335-41.
119. Pagel JM, Appelbaum FR, Eary JF, et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 2006; 107(5): 2184-91.
120. Ringhoffer M, Blumstein N, Neumaier B, et al. 188Re or 90Y- labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. Br J Haematol 2005; 130(4): 604-13.
121. Bunjes D. 188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia. Leuk Lymphoma 2002; 43(11): 2125-31.
122. Satoh M, Iida S, Shitara K. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Exp Opin Biol Ther 2006; 6(11): 1161-73.
123. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104(9): 2635-42.
124. Sicard H, Al Saati T, Delsol G, Fournie JJ. Synthetic phosphoantigens enhance human Vgamma9Vdelta2 T lymphocytes killing of non-Hodgkin's B lymphoma. Mol Med 2001; 7(10): 711-22.
125. Poupot M, Fournie JJ. Non-peptide antigens activating human Vgamma9/Vdelta2 T lymphocytes. Immunol Lett 2004; 95(2): 129-38.
126. Bonneville M, Scotet E. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol 2006; 18(5): 539-46.
127. Belmant C, Decise D, Fournie JJ. Phosphoantigens and aminobisphosphonates: New leads targeting gamma delta T lymphocytes for cancer immunotherapy. Drug Discov Today: Therapeutic Strategies. 2006; 3(1): 17-23.
128. Sicard H, Ingoure S, Luciani B, et al. In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J Immunol 2005; 175(8): 5471-80.
129. Gertner-Dardenne J, Bonnafous C, Bezombes C, et al. Bromohydrin pyrophosphate enhances antibody-dependent cell- mediated cytotoxicity induced by therapeutic antibodies. Blood 2009; 113(20): 4875-84.
130. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321(5891): 974-7.
131. Nagorsen D, Bargou R, Ruttinger D, Kufer P, Baeuerle PA, Zugmaier G. Immunotherapy of lymphoma and leukemia with T- cell engaging BiTE antibody blinatumomab. Leuk Lymphoma 2009; 50(6): 886-91.
132. d'Argouges S, Wissing S, Brandl C, et al. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell- engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res 2009; 33(3): 465-73.
133. Sola C, Andre P, Lemmers C, et al. Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proceedings of the National Academy of Sciences of the United States of America 2009; 106(31): 12879-84.
134. Romagne F, Andre P, Spee P, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009; 114(13): 2667-77.
135. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009; 69(12): 4941-4.
136. Jordan JL, Arndt JW, Hanf K, et al. Structural understanding of stabilization patterns in engineered bispecific Ig-like antibody molecules. Proteins 2009; 77(4): 832-41.
137. Kipriyanov SM. Generation of bispecific and tandem diabodies. Methods Mol Biol 2009; 562: 177-93.
138. Riechelmann H, Wiesneth M, Schauwecker P, et al. Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial. Cancer Immunol Immunother 2007; 56(9): 1397-406.
139. Shen J, Zhu Z. Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer. Curr Opin Mol Ther 2008; 10(3): 273-84.
140. Sebastian M, Kiewe P, Schuette W, et al. Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study. J Immunother 2009; 32(2): 195-202.